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Although surgical resection and liver transplantation are the only treatment modalities that enable
prolonged survival in patients with hepatocellular carcinoma (HCC), the majority of HCC patients presents
with advanced disease and do not undergo resective or ablative therapy. Transarterial chemoembolization
(TACE) is indicated in intermediate/advanced stage unresectable HCC even in the setting of portal vein
involvement (excluding main portal vein). Sorafenib has been shown to improve survival of patients with
advanced HCC in two controlled randomized trials. Yttrium 90 is a safe microembolization treatment that
can be used as an alternative to TACE in patients with advanced liver only disease or in case of portal vein
thrombosis. External beam radiation can be helpful to provide local control in selected unresectable HCC.
These different treatment modalities may be combined in the treatment strategy of HCC and also used as
a bridge to resection or liver transplantation. Patients should undergo formal multidisciplinary evaluation
prior to initiating any such treatment in order to individualize the best available options.
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Introduction
Death rates from hepatocellular cancer (HCC) in the United
States have increased by 47% in males and 27% in females since
1990.1 These data reflect a rising incidence, and only a slight
improvement of five-year overall survival of 11%.1 The majority
of HCC patients present with advanced disease that is not ame-
nable to resection or orthotopic liver transplantation (OLT); 84%
with extensive intrahepatic disease do not undergo any resective
or ablative therapy.2 However, there has been an increase in the use
of noninvasive local and regional therapies in recent years.2
Several ‘noncurative’ therapy forms have gained traction in the
management of HCC. Among these, four of the most widely
employed modalities are summarized in this Consensus State-
ment review: transarterial chemoembolization (TACE), systemic
therapy with non-chemotherapeutic agents, 90Yttrium micro-
sphere radioembolization treatment (Y90), and photon or proton
radiotherapy. It is mandatory that patients undergo a formal
multidisciplinaryevaluation prior to initiating any such treatment
in order to balance the available options.
The role of TACE and emerging therapies
TACE
TACE was introduced in 1977 by Yamada et al., who exploited
HCC’s preferential blood supply from the hepatic artery to deliver
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chemotherapy without damaging the surrounding liver paren-
chyma.3,4 A decade later, the observation that lipiodol, an iodi-
nated ester derived from poppy-seed oil, can be selectively taken
up and retained by primary HCC and some hepatic metastases of
colonic and neuroendocrine tumors led to the popularization of
this compound as a component of the injected TACE cocktail.5–7
Moreover, lipiodol effectively increases the local concentrations of
chemotherapeutic agents, leading to cancer cell death by ischemia
as well as by chemotherapeutic mechanisms.
Controversy persists regarding the choice of the chemothera-
peutics used for TACE. Drugs including doxorubicin, epirubicin,
cisplatin, mitomicin C, and mitoxantrone have been used with
TACE. Currently, there is no ‘best’ chemotherapeutic agent. The
most common chemotherapeutic drug used as a sole agent is
doxorubicin, whereas the combination of cisplatin, doxorubicin,
andmitomycin C is the most common combination drug regimen
for embolization treatment of HCC.8 All of these drugs have high
hepatic extraction with concurrent low systemic drug exposure.
Despite the favorable pharmacokinetics, most randomized con-
trolled trials have failed to demonstrate an advantage of one agent
over another.9 In one study, cisplatin was shown to be more effec-
tive than doxorubicin as a single agent against HCC; however, this
improved effectiveness could not be correlated with improved
survival.10 Some suggest that injectable volumes of chemotherapy
and long-term arterial patency were improved by embolizing
the tumor-feeding vessel(s) only after the entire dose of chemo-
therapy had been delivered.11
In the United States, the most common combination is the
mixture of cisplatin 100 mg (Bristol Myers Squibb, Princeton,
NJ), doxorubicin 50 mg (Adriamycin; Pharmacia-Upjohn,
Kalamazoo, MI) and mitomycin C 10 mg (Bedford Laboratories,
Bedford, OH) diluted in 10 ml of water-soluble contrast medium
(Omnipaque; Winthrop Pharmaceuticals, New York, NY).12–14
This cocktail is then emulsified in an equivalent volume of lipi-
odol. Several embolic agents may be injected in order to enhance
the effects of transcatheter intra-arterial drug delivery. The
intended purpose of embolization is two-fold: to prevent washout
of the drug at the site of tumor and to induce ischemic necrosis.
Usually, the injection of embolic particles follows the injection of
the chemotherapeutic mixture, yet, some centers favor mixing the
particles in slurry with the chemotherapeutic drugs and oil.11
Gelatin sponge powder and pledgets and polyvinyl alcohol are the
most commonly used agents for TACE.11
Patient selection and indications for TACE
TACE is a preferred treatment for palliation of unresectable
HCC14–16 and is also employed as an adjunctive therapy to liver
resection or as a bridge to OLT, as well as prior to or after radio-
frequency ablation.17–21 However, it is not clear that all of patients
with these indications benefit from TACE since in patients with
advanced liver disease, treatment-induced liver failure may offset
the anti-tumoral effect or survival benefit of the intervention.
Key predictors of outcome other than those reflective of tumor
burden, such as tumor size, vascular invasion, and a-fetoprotein
(AFP) levels, include liver functional impairment (Child-Pugh
score, bilirubin), performance status (Karnofsky index, Eastern
Co-operative Oncology Group performance status scale), and
response to treatment.
The best candidates for TACE are patients with unresectable
lesions and preserved liver function, asymptomatic lesions,
without vascular invasion or extrahepatic spread. Many prognos-
ticating systems exist for HCC, but the Child-Pugh nominal liver
staging system was the most accurate in predicting survival of
patients with unresectable HCC treated with TACE,22 emphasizing
the importance of baseline liver function. For many years the use
of TACE was based on non-randomized data showing safety
and effectiveness of the technique by tumor response (level of
evidence: 2 and/or 3).12,20,23 In 2002, however, two studies showed
a statistically significant survival advantage with the use of
TACE versus best supportive care in selected patients with well-
preserved liver function (level of evidence: 1).14,16 Llovet et al.
prospectively studied the survival outcomes in patients treated
with fixed interval TACE, trans arterial embolization (TAE)
and supportive measures.14 This trial was stopped early when a
survival benefit for TACE became clear. Because the study was
discontinued, the TACE vs. TAE question was not answered. In a
second randomized controlled trial, Lo et al. reported on select
patients with unresectable HCC treated with TACE or supportive
care and demonstrated that TACE significantly improved sur-
vival.16 In this trial, the most common complications of patients
treated with TACE were fever in 32.8%, abdominal pain (26%),
vomiting (17%), ascites (5.2%), and gastrointestinal bleeding
(4.2%). Other large and small series are consistent with these
findings.20,22,24–28 These results suggest that future prospective
randomized studies in advanced HCC should include TACE as the
standard of care study arm while comparing equal-risk patient
populations. There is now some evidence that patients with portal
vein thrombosis (PVT) may tolerate TACE as well. A study by
Georgiades et al. evaluated the safety of TACE in 32 patients with
PVT and identified key prognostic factors and survival.29 Median
overall survival was 9.5 months, and the Child-Pugh numerical
disease stage was the prognostic factor most strongly related to
survival, while there was no evidence of TACE-related hepatic
infarction or acute liver failure.
TACE with drug-eluting microspheres has recently been added
to the spectrum of intra-arterial therapies for liver cancer. Drug
eluting microspheres injected into the tumor-feeding artery may
offer delivery of chemotherapy and embolization with sustained
and controlled drug release over time. There are currently two
types of microspheres available for drug loading: DC Bead™
microspheres (Biocompatibles, UK) and the recently introduced
superabsorbent polymer (SAP) Quadrasphere™ (Hepasphere™
for Europe) microspheres (Biosphere Medical, Inc). These micro-
spheres have different characteristics and can be loaded with a few
chemotherapeutics, but are available in the United States only in
IRB and FDA Investigational Device Exemption approved trials.
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Consensus statement
1. TACE is a standard for intermediate/advanced stage unresect-
able HCC even in the setting of portal vein involvement
(excluding main portal vein)
2. TACE is useful to better select patients for OLT (predictor of
tumor biology)
3. There is currently emerging evidence that combination of
loco-regional catheter-based approaches and targeted therapy
is efficacious and has limited toxicity
4. Technical note: Conventional (oil-based) TACE is likely to be
phased out and replaced by drug-eluting microspheres TACE
(DEB-TACE).
Systemic therapy of HCC
Sorafenib, a multi-targeted anti-VEGF receptor and raf kinase
inhibitor, is approved for the treatment of unresectable HCC30
based on the results of a double-blinded, randomized phase III
trial evaluating sorafenib versus placebo in patients with advanced
HCC and Child-Pugh A cirrhosis.31 This study, known as the
SHARP trial, showed an improvement in survival of 10.7 months
in the sorafenib group versus 7.9 months in the placebo group
(p < 0.001, HR = 0.69). Considering the level I evidence this study
provides, sorafenib is considered an appropriate choice of therapy
for metastatic HCC and locally advanced disease that is not oth-
erwise amenable to a local therapy modality. Despite the improve-
ment in overall survival noted in the SHARP trial, there were few
radiographic responses. However, seventy one per cent of patients
on sorafenib had stable disease as best response.Data from a phase
II study evaluating sorafenib in advanced HCC32 showed that
triphasic CT scans allow an estimate of tumor necrosis/volume
ratio, and that this measure correlates with response including
stable disease.33 While prospective studies to test this correlation
are being conducted, triphasic CT scan imaging or enhanced MRI
are the appropriate modalities to assess response in HCC. AFP
plasma level, though not recognized as a surrogate marker for
response,34 may be valuable and complementary in patients whose
tumors express AFP.
How to utilize sorafenib in patients with HCC and advanced
cirrhosis was the subject of several reported studies. In the phase
II study evaluating sorafenib in HCC,32 28% of patients had
Child-Pugh B cirrhosis. While the pharmacokinetics were com-
parable for the Child-Pugh A and B patients, there was a more
frequent worsening of liver function among the Child-Pugh B
patients, represented by an increase in bilirubin in 40% of Child-
Pugh B compared to 18% Child-Pugh A patients,35 although a not
harmful inhibitory effect of UGT1A1 leading to decreased biliru-
bin glucuronidation could partake in this effect. Median time to
progression for Child-Pugh A was 21 weeks versus 13 for Child-
Pugh B patients, and overall survival was 41 weeks versus 14
weeks, respectively. In a phase I study evaluating two different
doses of sorafenib in Japanese patients with advanced HCC,36
there were no substantial differences in the incidence of adverse
events between Child–Pugh A and B groups. In a third study
evaluating sorafenib in patients with different malignancies, but
with underlying organ dysfunction, the most commonly reported
drug-limiting toxicity among patients with elevated bilirubin at
baseline was further elevation of bilirubin.37 It is thus recom-
mended to reduce the sorafenib dose for bilirubin 1.5–3 ¥ upper
limit of normal (ULN), and to avoid sorafenib for bilirubin above
3 ¥ ULN. More data are needed to define appropriately the safety
and efficacy of sorafenib in patients with HCC and Child-Pugh B
cirrhosis, currently the subject of further studies.
Another randomized phase III trial with the same inclusion
criteria and design as the SHARP trial was conducted in the Asia-
Pacific region in patients with more advanced stage of disease and
mainly hepatitis B etiology; there was a statistically significant
improvement in survival for sorafenib compared to placebo (p =
0.014), but not to the same magnitude as in the SHARP trial.38 In
this study, patients had generally a worse performance status in
addition to more extensive disease, which may partly explain the
difference in the magnitude of sorafenib benefit between those
two studies. There could however be a hepatitis B-related influ-
ence on outcome. In a retrospective evaluation of the phase II trial
evaluating sorafenib in patients with advanced HCC,32 there was
a trend towards a survival advantage for the hepatitis C (12.4
months) versus hepatitis B patients (7.3 months) (Huitzil et al.,
ASGO GI Symposium 2008, Abstract 173). A possible HCV-1 core
protein associated with an increase in raf kinase activity, suggest-
ing a preferential activity of sorafenib in patients with HCC of
HCV origin39 is supported by a sub-group analysis of patients
from the SHARP trial with hepatitis C-associated HCC (Bolondi
et al., ASGO GI Symposium 2008, Abstract 129). It was noted that
these patients treated with sorafenib had a median survival of 14
months compared to the whole sorafenib treated group of 10.7
months. The outcome of those 18% of patients in the SHARP
trial with hepatitis B, however, remains to be reported. Until then,
sorafenib remains indicated for all appropriate patients with
unresectable HCC, while the underlying hepatitis etiology may
be important in future study design.
Several other therapies have been studied as single agent or in
combination in advanced HCC, and are being evaluated further in
larger phase III trials. Among the anti-angiogenic therapies, beva-
cizumab has been studied extensively in patients with advanced
HCC as single agent,40,41 or in combination.41–43 The positive
outcome with a combination of bevacizumab and erlotinib, with
a median progression free survival of 39 weeks and a median
overall survival of 68 weeks,44 is now being further evaluated in a
randomized phase II study that includes a sorafenib monotherapy
arm. Sunitinib, another potent anti-angiogenic, was the subject of
two single agent studies,45,46 and is currently being analyzed for
superiority in a randomized phase III against sorafenib. ABT 869,
an inhibitor of angiogenesis and platelet-derived growth factor
receptor function,47 and brivanib, a dual inhibitor of vascular
endothelial growth factor and fibroblast growth factor receptors,48
are also the subject of large randomized studies. Sorafenib is also
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the subject of two large randomized phase III studies, either in
combination with erlotinib based on previous phase I experi-
ence,49 or in combination with doxorubicin based on a random-
ized phase II study (Abou-Alfa et al., ASGO GI Symposium 2008,
Abstract 128). Unfortunately, this wealth of clinic trials raises a
serious question about the use of resources, as HCC remains a
relatively rare disease in the United States, and as a consensus on
conducting clinical trials that evaluate novel therapies in random-
ized phase II studies before committing to large randomized phase
III studies is needed in order to optimize clinical trial resources.
Due to limited data, the use of sorafenib is currently not rec-
ommended outside a clinical trial in the adjuvant or neoadjuvant
setting, nor as a bridge to transplant. Recently presented data on
the use of sorafenib versus placebo one to three months after
TACE have shown no improvement in time-to-progression (5.4
versus 3.7 months respectively, HR = 0.87; 95% CI, 0.70–1.09; p =
0.25) (Okita et al., ASGO GI Symposium 2010, Abstract 128), and
thus do not support such combined therapy approach in clinical
practice. Periprocedural sorafenib at the start of TACE and
beyond is currently being studied by an ECOG intergroup trial.50
An earlier use of anti-angiogenic therapy may be more valuable in
curbing the VEGF surge that can be expected after TACE.51
Consensus statement
1. Sorafenib is the standard agent for systemic therapy of
advanced HCC
2. RECIST criteria are poor parameters for assessing anti-tumor
efficacy, but tumor necrosis may be an accurate surrogate if
early data can be validated
3. HCC etiology and the extent of cirrhosis influence outcomes of
systemic therapies
4. Managing patients with HCC and advanced cirrhosis may
require special guidelines
5. Novel systemic agents and combination therapies require
further studies
Radioembolization through 90Yttrium
microsphere therapy
Growing evidence supports a role of radioembolization for the
treatment of HCC, and patients should be selected for this treat-
ment modality by a multidisciplinary team consensus of hepa-
tologists, oncologists, surgeons and interventional radiologists.
The emerging role of 90Yttrium (Y90) radioembolization may not
just be limited by the stage of the disease.
Radioembolization for patients within
transplant criteria
The use of surgical options is the standard for treatment for these
patients. Patients within Milan criteria, i.e. a single lesion less than
5 cm or up to 3 lesions all less than 3 cm, are eligible for OLT.52
Resection is possible only if liver function is preserved. Limited
availability of donor organs for OLT and the drop out of patients
due to tumor progression limit the number of patients who
are able to undergo OLT. Thermal ablation (e.g. radiofrequency
ablation) has a limited role due to the risk of tract seeding, and
challenges related to size and location of tumors. Radioemboliza-
tion has been shown to limit the progression of the disease, which
can allow the patient more time to wait for donor organs and thus
increase their chance of undergoing OLT.53 Thus, it has a role of
bridging patients to OLT.
Radioembolization for patients beyond
transplant criteria
The patients who are outside transplant criteria (due to
size/number of tumors) but do not have malignant PVT or extra-
hepatic metastatic HCC may also be candidates for radioembo-
lization. The use of radioembolization in these patients has been
shown to downstage the disease to within transplant criteria. This
allows patients who were initially outsideMilan criteria to become
eligible for OLT. There is an increase in overall survival in these
patients as well.53 Lewandowski et al. recently published their
experience of downstaging using transarterial therapies for
HCC.54 Their data suggest a superior ability of radioembolization
to downstage HCC when compared to TACE. The recurrence free
survival and overall survival after OLT in the downstaged patients
has yet to be compared to that of the patients who were already
within transplant criteria to determine the efficacy of downstag-
ing. A thorough radiologic-pathologic correlative analysis has
been completed, describing very high rates of complete tumor
necrosis at the microscopic level.55
Radioembolization for patients with advanced disease
Patients with PVT have been shown to have a favorable response
to treatment after radioembolization.56 The presence of malignant
PVT excludes these patients from the transplant criteria, whereas
its presence is not a contraindication to radioembolization with
Y90. Systemic therapy with sorafenib has been shown to have a
statistically significant improvement in survival in patients with
advanced disease.31 The hepatic artery is the sole vascular supply
to the parenchyma in the presence of PVT, which renders embolic
therapies relatively contraindicated. However, Y90 may be used in
these cases due to its minimal embolic effect.56 A survival benefit
(10.1–13.4 months from treatment) has been shown with the
use of radioembolization in patients with malignant vascular
involvement.56 A survival benefit, however, has not been shown
in patients with distant metastases.57
Conclusion
The largest comprehensive analysis on the role of radioemboliza-
tion for HCC was recently published.57 The data on 291 patients,
substratified by various stages, suggest that radioembolization is a
safe and effective treatment modality, with promising response
rates and associated survival. Applications of radioembolization
include bridging and downstaging potential transplant candi-
dates, as well as palliation in patients with multifocal disease,
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particularly those with vascular invasion. Potential advantages
over TACE include: a) fewer treatment sessions required, and b)
treatment can be performed on an outpatient basis.
Consensus statement
1. Y90 is a safe microembolization treatment and can be admin-
istered in the outpatient setting.
2. Y90 could be considered for treating HCC in the following
scenarios:
– downstaging/bridging to transplantation or resection
– portal vein thrombosis
– advanced disease.
3. There are no level 1 data for Y90 compared to other regional
therapies. Considerations of efficacy and safety (given cirrho-
sis) have to be made on an individual basis.
Photon and proton radiotherapy
Technological advances and a better understanding of partial liver
tolerance of radiation therapy (RT) have improved our ability to
deliver tumoricidal doses of RT safely to HCCs, and have led to a
resurgence of interest in curative-intent treatment of HCC using
RT. Outlined below are the key developments in the use of RT for
HCC:
Partial liver irradiation
The development of three-dimensional conformal RT has enabled
high dose RT to be directed to the tumor while sparing the non-
tumor-bearing surrounding liver parenchyma from these high
doses. Using a mathematical model that predicts the risk of
radiation-induced liver disease based on dose and fractional
volume receiving a given dose, the probability of radiation toxicity
can be minimized while still being able to escalate the dose to a
small volume.58
Image-guidance and targeting
Technological advances in RT now facilitate greater ability to
account for respiratory movement of liver tumors during treat-
ment. Tumors can be localized during breathing by using the
diaphragm as a surrogate for liver position, via four-dimensional
(4D) CT scanning to define the spatial coordinates of the tumor
during all phases of respiration, via volumetric cone-beam CT
scanning, or using radiopaque fiducials implanted in the vicinity
of the tumor. Tumors can be treated during free breathing based
on 4D CT derived composite target volumes (coordinates of the
tumor during all phases of breathing) or via real-time tracking of
tumor motion and gating or robotic control of the treatment
beam, during breathholds using active breathing control, or
during end-expiratory gating.59 These techniques improve the
precision of radiation delivery and thereby limit collateral normal
tissue toxicity.
External beam radiation therapy
Promising clinical data from multiple studies suggest that HCCs
are indeed radiosensitive. Sustained local control rates ranging
from 71% to 100% have been reported following 30–90 Gy deliv-
ered over 1–8 weeks.59,60 Investigators from Michigan have used
conformal RT (1.5 Gy twice daily over 6–8 weeks) with concurrent
hepatic arterial fluorodeoxyuridine to treat HCCs safely to
doses as high as 90 Gy, with a resulting median survival of 15.2
months.61 Analysis of these data suggested that doses greater than
75 Gy resulted in more durable in-field local control than lower
doses. A prospective French phase II trial administered 66 Gy in
33 fractions to HCCs ineligible for curative therapies and noted
92% tumor responses and 78% 1-year local control rates.62 Using
higher doses and fewer fractions (hypofractionated RT), Cana-
dian researchers have noted excellent local control rates ranging
from 70% to 90% when the radiation beam can be directed from
multiple planes (stereotactic RT) converging on the tumor, the
majority of the liver can be spared from irradiation, and treatment
is image-guided.60,63,64 Across all partial liver radiation paradigms,
the most common site of first recurrence is intrahepatic, however
outside the high dose-irradiated volume; toxicity is greater in
Child-Pugh B compared to Child-Pugh A patients.
Proton irradiation
In contrast to photon irradiation, where the dose delivered to the
tumor is limited by the entrance and exit doses that can poten-
tially harm normal tissues, accelerated proton beams deposit dose
within the tumor without exiting through normal tissues beyond
the tumor. Japanese investigators have reported results of treat-
ment with 72 Gy in 16 fractions of proton beam therapy for 162
patients with 192 unresectable HCCs.65 The 5-year local control
rate of 87% and overall survival rate of 23.5% in the absence of
significant toxicity are clinically noteworthy. Furthermore, the
impressive 5-year survival rate of 53.5% achieved in a subset of 50
patients with solitary tumors and Child-Pugh A cirrhosis suggests
that proton beam therapy is safe and efficacious in the treatment
of HCC, and that the results may compare favorably to other
curative treatments. Other groups have reported similar results
with proton beam therapy of HCCs as well.66,67
Combination of RT with other therapies
Tumors treated with TACE, an established treatment for unresec-
table HCC, often do not achieve durable local responses.68,69 RT
has been combined with TACE to overcome treatment resistance.
Korean researchers initially noted >60% response rates and a
significant drop in tumor markers levels using this combina-
tion treatment strategy.70,71 TACE followed by RT was reported
to improve overall survival over TACE alone in a retrospective
analysis of this experience. Similar results have been reported by
other groups.72–74 To address the persisting challenge of out-of-
field intraheptic failures despite improved in-field local control,
concurrent intra-arterial 5-FU and RT followed by monthly 5-FU
and cisplatin has shown some promise.75
Treatment of unfavorable tumors
Multiple groups have reported favorable outcomes in patients
with tumoral PVT treated with RT.60 Response rates range from
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37.5 to 100%, and median survival durations range from 3.8 to
10.7 months.60 Proton beam therapy has also been safe and effec-
tive in the treatment of patients with limited treatment options,
i.e. recurrent HCCs after prior proton therapy, tumoral PVT, and
Child-Pugh Class C cirrhosis.59
Consensus statement
1. Radiation therapy can provide local control for some unresec-
table HCC lesions.
2. Improved understanding of partial liver RT tolerance and
better RT planning and delivery have advanced the ability to
escalate radiation dose to unresectable HCCs without causing
undue toxicity.
3. Hypofractionation, stereotactic treatment and proton beam
therapy are further expanding the horizons of treatment.
4. Strategies that combine RT with other therapies merit contin-
ued evaluation.
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